Benign prostatic hyperplasia explained

Benign prostatic hyperplasia
Synonyms:Benign enlargement of the prostate (BEP, BPE), adenofibromyomatous hyperplasia, benign prostatic hypertrophy, benign prostatic obstruction
Field:Urology
Symptoms:Frequent urination, trouble starting to urinate, weak stream, inability to urinate, loss of bladder control
Complications:Urinary tract infections, bladder stones, kidney failure
Onset:Age over 40
Causes:Unclear
Risks:Family history, obesity, type 2 diabetes, not enough exercise, erectile dysfunction
Diagnosis:Based on symptoms and examination after ruling out other possible causes
Differential:Heart failure, diabetes, prostate cancer
Treatment:Lifestyle changes, medications, a number of procedures, surgery
Medication:Alpha blockers such as terazosin, 5α-reductase inhibitors such as finasteride
Frequency:94 million men affected globally (2019)

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.[1]

The cause is unclear. Risk factors include a family history, obesity, type 2 diabetes, not enough exercise, and erectile dysfunction. Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms. The underlying mechanism involves the prostate pressing on the urethra and thereby making it difficult to pass urine out of the bladder. Diagnosis is typically based on symptoms and examination after ruling out other possible causes.

Treatment options include lifestyle changes, medications, a number of procedures, and surgery.[1] In those with mild symptoms, weight loss, decreasing caffeine intake, and exercise are recommended, although the quality of the evidence for exercise is low.[1] [2] In those with more significant symptoms, medications may include alpha blockers such as terazosin or 5α-reductase inhibitors such as finasteride.[3] Surgical removal of part of the prostate may be carried out in those who do not improve with other measures. Some herbal medicines that have been studied, such as saw palmetto, have not been shown to help. Other herbal medicines somewhat effective at improving urine flow include beta-sitosterol[4] from Hypoxis rooperi (African star grass), pygeum (extracted from the bark of Prunus africana),[5] pumpkin seeds (Cucurbita pepo), and stinging nettle (Urtica dioica) root.[6]

, about 94 million men aged 40 years and older are affected globally.[7] BPH typically begins after the age of 40. The prevalence of clinically diagnosed BPH peaks at 24% in men aged 75–79 years.[7] Based on autopsy studies, half of males aged 50 and over are affected, and this figure climbs to 80% after the age of 80.[7] Although prostate specific antigen levels may be elevated in males with BPH, the condition does not increase the risk of prostate cancer.[8]

Signs and symptoms

BPH is the most common cause of lower urinary tract symptoms (LUTS), which are divided into storage, voiding, and symptoms which occur after urination. Storage symptoms include the need to urinate frequently, waking at night to urinate, urgency (compelling need to void that cannot be deferred), involuntary urination, including involuntary urination at night, or urge incontinence (urine leak following a strong sudden need to urinate).[9] Voiding symptoms include urinary hesitancy (a delay between trying to urinate and the flow actually beginning), intermittency (not continuous),[10] involuntary interruption of voiding, weak urinary stream, straining to void, a sensation of incomplete emptying, and uncontrollable leaking after the end of urination.[11] [12] [13] These symptoms may be accompanied by bladder pain or pain while urinating, called dysuria.[14]

Bladder outlet obstruction (BOO) can be caused by BPH.[15] Symptoms are abdominal pain, a continuous feeling of a full bladder, frequent urination, acute urinary retention (inability to urinate), pain during urination (dysuria), problems starting urination (urinary hesitancy), slow urine flow, starting and stopping (urinary intermittency), and nocturia.[16]

BPH can be a progressive disease, especially if left untreated. Incomplete voiding results in residual urine or urinary stasis, which can lead to an increased risk of urinary tract infection.[17]

Causes

Hormones

Most experts consider androgens (testosterone and related hormones) to play a permissive role in the development of BPH. This means that androgens must be present for BPH to occur, but do not necessarily directly cause the condition. This is supported by evidence suggesting that castrated boys do not develop BPH when they age. In a study of 26 eunuchs from the palace of the Qing dynasty still living in Beijing in 1960, the prostate could not be felt in 81% of the studied eunuchs.[18] The average time since castration was 54 years (range, 41–65 years). On the other hand, some studies suggest that administering exogenous testosterone is not associated with a significant increase in the risk of BPH symptoms, so the role of testosterone in prostate cancer and BPH is still unclear. Further randomized controlled trials with more participants are needed to quantify any risk of giving exogenous testosterone.[19]

Dihydrotestosterone (DHT), a metabolite of testosterone, is a critical mediator of prostatic growth. DHT is synthesized in the prostate from circulating testosterone by the action of the enzyme 5α-reductase, type 2. DHT can act in an autocrine fashion on the stromal cells or in paracrine fashion by diffusing into nearby epithelial cells. In both of these cell types, DHT binds to nuclear androgen receptors and signals the transcription of growth factors that are mitogenic to the epithelial and stromal cells. DHT is ten times more potent than testosterone because it dissociates from the androgen receptor more slowly. The importance of DHT in causing nodular hyperplasia is supported by clinical observations in which an inhibitor of 5α-reductase such as finasteride is given to men with this condition. Therapy with a 5α-reductase inhibitor markedly reduces the DHT content of the prostate and, in turn, reduces prostate volume and BPH symptoms.[20] [21]

Testosterone promotes prostate cell proliferation,[22] but relatively low levels of serum testosterone are found in patients with BPH.[23] [24] One small study has shown that medical castration lowers the serum and prostate hormone levels unevenly, having less effect on testosterone and dihydrotestosterone levels in the prostate.[25]

Besides testosterone and DHT, other androgens are also known to play a crucial role in BPH development. 11-oxygenated steroids (pregnanes) have been identified are precursors to 11-oxygenated androgens which are also potent agonists for the androgen receptor.[26] Specifically, steroids like 11β-hydroxyprogesterone and 11-ketoprogesterone can be converted to 11-ketodihydrotestosterone, an 11-oxo form of DHT with the same potency. These precursors have also been detected in tissue biopsy samples from patients with BPH, as well as in their serum levels.[27] [28] [29] Besides that, androgens biosythnesized via a backdoor pathway can contribute to the development of BPH.[27]

While there is some evidence that estrogen may play a role in the cause of BPH, this effect appears to be mediated mainly through local conversion of androgens to estrogen in the prostate tissue rather than a direct effect of estrogen itself.[30] In canine in vivo studies castration, which significantly reduced androgen levels but left estrogen levels unchanged, caused significant atrophy of the prostate.[31] Studies looking for a correlation between prostatic hyperplasia and serum estrogen levels in humans have generally shown none.[32]

In 2008, Gat et al. published evidence that BPH is caused by failure in the spermatic venous drainage system resulting in increased hydrostatic pressure and local testosterone levels elevated more than 100 fold above serum levels.[33] If confirmed, this mechanism explains why serum androgen levels do not seem to correlate with BPH and why giving exogenous testosterone would not make much difference.

Diet

Studies indicate that dietary patterns may affect development of BPH, but further research is needed to clarify any important relationship.[34] Studies from China suggest that greater protein intake may be a factor in development of BPH. Men older than 60 in rural areas had very low rates of clinical BPH, while men living in cities and consuming more animal protein had a higher incidence.[35] [36] On the other hand, a study in Japanese-American men in Hawaii found a strong negative association with alcohol intake, but a weak positive association with beef intake.[37] In a large prospective cohort study in the US (the Health Professionals Follow-up Study), investigators reported modest associations between BPH (men with strong symptoms of BPH or surgically confirmed BPH) and total energy and protein, but not fat intake.[38] There is also epidemiological evidence linking BPH with metabolic syndrome (concurrent obesity, impaired glucose metabolism and diabetes, high triglyceride levels, high levels of low-density cholesterol, and hypertension).[39]

Degeneration

Benign prostatic hyperplasia is an age-related disease. Misrepair-accumulation aging theory[40] suggests that development of benign prostatic hyperplasia is a consequence of fibrosis and weakening of the muscular tissue in the prostate.[41] The muscular tissue is important in the functionality of the prostate, and provides the force for excreting the fluid produced by prostatic glands. However, repeated contractions and dilations of myofibers will unavoidably cause injuries and broken myofibers. Myofibers have a low potential for regeneration; therefore, collagen fibers need to be used to replace the broken myofibers. Such misrepairs make the muscular tissue weak in functioning, and the fluid secreted by glands cannot be excreted completely. Then, the accumulation of fluid in glands increases the resistance of muscular tissue during the movements of contractions and dilations, and more and more myofibers will be broken and replaced by collagen fibers.[42]

Pathophysiology

As men age, the enzymes aromatase and 5-alpha reductase increase in activity. These enzymes are responsible for converting androgen hormones into estrogen and dihydrotestosterone, respectively. This metabolism of androgen hormones leads to a decrease in testosterone but increased levels of DHT and estrogen.

Both the glandular epithelial cells and the stromal cells (including muscular fibers) undergo hyperplasia in BPH. Most sources agree that of the two tissues, stromal hyperplasia predominates, but the exact ratio of the two is unclear.[43]

Anatomically the median and lateral lobes are usually enlarged, due to their highly glandular composition. The anterior lobe has little in the way of glandular tissue and is seldom enlarged. (Carcinoma of the prostate typically occurs in the posterior lobe – hence the ability to discern an irregular outline per rectal examination). The earliest microscopic signs of BPH usually begin between the age of 30 and 50 years old in the PUG, which is posterior to the proximal urethra. In BPH, the majority of growth occurs in the transition zone (TZ) of the prostate. In addition to these two classic areas, the peripheral zone (PZ) is also involved to a lesser extent. Prostatic cancer typically occurs in the PZ. However, BPH nodules, usually from the TZ are often biopsied anyway to rule out cancer in the TZ. BPH can be a progressive growth that in rare instances leads to exceptional enlargement. In some males, the prostate enlargement exceeds 200 to 500 grams.[44] This condition has been defined as giant prostatic hyperplasia (GPH).[44]

Diagnosis

The clinical diagnosis of BPH is based on a history of LUTS (lower urinary tract symptoms), a digital rectal exam, and exclusion of other causes of similar signs and symptoms. The degree of LUTS does not necessarily correspond to the size of the prostate. An enlarged prostate gland on rectal examination that is symmetric and smooth supports a diagnosis of BPH. However, if the prostate gland feels asymmetrical, firm, or nodular, this raises concern for prostate cancer.

Validated questionnaires such as the American Urological Association Symptom Index (AUA-SI), the International Prostate Symptom Score (I-PSS), and more recently the UWIN score (urgency, weak stream, incomplete emptying, and nocturia) are useful aids to making the diagnosis of BPH and quantifying the severity of symptoms.[45] [46]

Laboratory investigations

Urinalysis is typically performed when LUTS are present and BPH is suspected to evaluate for signs of a urinary tract infection, glucose in the urine (suggestive of diabetes), or protein in the urine (suggestive of kidney disease). Bloodwork including kidney function tests and prostate specific antigen (PSA) are often ordered to evaluate for kidney damage and prostate cancer, respectively. However, checking blood PSA levels for prostate cancer screening is controversial and not necessarily indicated in every evaluation for BPH. Benign prostatic hyperplasia and prostate cancer are both capable of increasing blood PSA levels and PSA elevation is unable to differentiate these two conditions well. If PSA levels are checked and are high, then further investigation is warranted. Measures including PSA density, free PSA, rectal examination, and transrectal ultrasonography may be helpful in determining whether a PSA increase is due to BPH or prostate cancer.

Imaging and other investigations

Uroflowmetry is done to measure the rate of urine flow and total volume of urine voided when the subject is urinating.[47]

Abdominal ultrasound examination of the prostate and kidneys is often performed to rule out hydronephrosis and hydroureter. Incidentally, cysts, tumours, and stones may be found on ultrasound. Post-void residual volume of more than 100 ml may indicate significant obstruction.[48] Prostate size of 30 cc or more indicates enlargement of the prostate.[49]

Prostatic calcification can be detected through transrectal ultrasound (TRUS). Calcification is due to solidification of prostatic secretions or calcified corpora amylacea (hyaline masses on the prostate gland). Calcification is also found in a variety of other conditions such as prostatitis, chronic pelvic pain syndrome, and prostate cancer.[50] [51] For those with elevated levels of PSA, TRUS guided biopsy is performed to take a sample of the prostate for investigation.[52] Although MRI is more accurate than TRUS in determining prostate volume, TRUS is less expensive and almost as accurate as MRI. Therefore, TRUS is still preferred to measure prostate volume.[53]

Differential diagnosis

Medical conditions

The differential diagnosis for LUTS is broad and includes various medical conditions, neurologic disorders, and other diseases of the bladder, urethra, and prostate such as bladder cancer, urinary tract infection, urethral stricture, urethral calculi (stones), chronic prostatitis, and prostate cancer. Neurogenic bladder can cause urinary retention and cause symptoms similar to those of BPH. This may occur as a result of uncoordinated contraction of the bladder muscle or impairment in the timing of bladder muscle contraction and urethral sphincter relaxation. Notable causes of neurogenic bladder include disorders of the central nervous system such as Parkinson's disease, multiple sclerosis, and spinal cord injuries as well as disorders of the peripheral nervous system such as diabetes mellitus, vitamin B12 deficiency, and alcohol-induced nerve damage. Individuals affected by heart failure often experience nighttime awakenings to urinate due to redistribution of fluid accumulated in swollen legs.

Medications

Certain medications can increase urination difficulties by increasing bladder outlet resistance due to increased smooth muscle tone at the prostate or bladder neck and contribute to LUTS. Alpha-adrenergic agonist medications, such as decongestants with pseudoephedrine can increase bladder outlet resistance. In contrast, calcium channel blockers and anticholinergic medications can worsen urinary retention by promoting bladder muscle relaxation. Diuretic medications such as loop diuretics (e.g., furosemide) or thiazides (e.g., chlorthalidone) can cause or worsen urinary frequency and nighttime awakenings to urinate.

Management

When treating and managing benign prostatic hyperplasia, the aim is to prevent complications related to the disease and improve or relieve symptoms.[54] Approaches used include lifestyle modifications, medications, catheterisation and surgery.

Lifestyle

Lifestyle alterations to address the symptoms of BPH include physical activity,[55] decreasing fluid intake before bedtime, moderating the consumption of alcohol and caffeine-containing products and following a timed voiding schedule.

Patients can also attempt to avoid products and medications with anticholinergic properties that may exacerbate urinary retention symptoms of BPH, including antihistamines, decongestants, opioids, and tricyclic antidepressants; however, changes in medications should be done with input from a medical professional.[56]

Physical activity

Physical activity has been recommended as a treatment for urinary tract symptoms. A 2019 Cochrane review of six studies involving 652 men assessing the effects of physical activity alone, physical activity as a part of a self-management program, among others. However, the quality of evidence was very low and therefore it remains uncertain whether physical activity is helpful in men experiencing urinary symptoms caused by benign prostatic hyperplasia.[57]

Voiding position

Voiding position when urinating may influence urodynamic parameters (urinary flow rate, voiding time, and post-void residual volume).[58] A meta-analysis found no differences between the standing and sitting positions for healthy males, but that, for elderly males with lower urinary tract symptoms, voiding in the sitting position-- [59]

This urodynamic profile is associated with a lower risk of urologic complications, such as cystitis and bladder stones.

Medications

The two main medication classes for BPH management are alpha blockers and 5α-reductase inhibitors.[60]

Alpha blockers

Selective α1-blockers are the most common choice for initial therapy.[61] [62] [63] They include alfuzosin,[64] [65] doxazosin,[66] silodosin, tamsulosin, terazosin, and naftopidil. They have a small to moderate benefit at improving symptoms.[67] Selective alpha-1 blockers are similar in effectiveness but have slightly different side effect profiles.[68] Alpha blockers relax smooth muscle in the prostate and the bladder neck, thus decreasing the blockage of urine flow. Common side effects of alpha blockers include orthostatic hypotension (a head rush or dizzy spell when standing up or stretching), ejaculation changes, erectile dysfunction,[69] headaches, nasal congestion, and weakness. For men with LUTS due to an enlarged prostate, the effects of naftopidil, tamsulosin and silodosin on urinary symptoms and quality of life may be similar. Naftopidil and tamsulosin may have similar levels of unwanted sexual side effects but fewer unwanted side effects than silodosin.

Tamsulosin and silodosin are selective α1 receptor blockers that preferentially bind to the α1A receptor in the prostate instead of the α1B receptor in the blood vessels. Less-selective α1 receptor blockers such as terazosin and doxazosin may lower blood pressure. The older, less selective α1-adrenergic blocker prazosin is not a first line choice for either high blood pressure or prostatic hyperplasia; it is a choice for patients who present with both problems at the same time. The older, broadly non-selective alpha blocker medications such as phenoxybenzamine are not recommended for control of BPH.[70] Non-selective alpha blockers such as terazosin and doxazosin may also require slow dose adjustments as they can lower blood pressure and cause syncope (fainting) if the response to the medication is too strong.

5α-reductase inhibitors

The 5α-reductase inhibitors finasteride and dutasteride may also be used in people with BPH.[71] These medications inhibit the 5α-reductase enzyme, which, in turn, inhibits production of DHT, a hormone responsible for enlarging the prostate. Effects may take longer to appear than alpha blockers, but they persist for many years.[72] When used together with alpha blockers, no benefit was reported in short-term trials, but in a longer-term study (3–4 years) there was a greater reduction in BPH progression to acute urinary retention and surgery than with either agent alone, especially in people with more severe symptoms and larger prostates.[73] [74] [75] Other trials have confirmed reductions in symptoms, within 6 months in one trial, an effect that was maintained after withdrawal of the alpha blocker.[76] Side effects include decreased libido and ejaculatory or erectile dysfunction.[77] [78] The 5α-reductase inhibitors are contraindicated in pregnant women because of their teratogenicity due to interference with fetal testosterone metabolism, and as a precaution, pregnant women should not handle crushed or broken tablets.[79]

Phosphodiesterase inhibitors (PDE)

A 2018 Cochrane review of studies on men over 60 with moderate to severe lower urinary tract symptoms analyzed the impacts of phosphodiesterase inhibitors (PDE) in comparison to other drugs.[80] These drugs may improve urinary symptoms slightly and reduce urinary bother but may also cause more side effects compared to placebo. The evidence in this review found that there is probably no difference between PDE and alpha blockers, however when used in combination they may provide a greater improvement in symptoms (with more side effects). PDE also likely improves symptoms when used in combination with 5-alpha reductase inhibitors.

Several phosphodiesterase-5 inhibitors are also effective, but may require multiple doses daily to maintain adequate urine flow.[81] [82] Tadalafil, a phosphodiesterase-5 inhibitor, was considered then rejected by NICE in the UK for the treatment of symptoms associated with BPH.[83] In 2011, the U.S. Food and Drug Administration approved tadalafil to treat the signs and symptoms of benign prostatic hyperplasia, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously.[84]

Others

Antimuscarinics such as tolterodine may also be used, especially in combination with alpha blockers.[85] They act by decreasing acetylcholine effects on the smooth muscle of the bladder, thus helping control symptoms of an overactive bladder.[86]

Self-catheterization

Intermittent urinary catheterization is used to relieve the bladder in people with urinary retention. Self-catheterization is an option in BPH when it is difficult or impossible to completely empty the bladder.[87] Urinary tract infection is the most common complication of intermittent catheterization.[88] Several techniques and types of catheter are available, including sterile (single-use) and clean (multiple use) catheters, but, based on current information, none is superior to others in reducing the incidence of urinary tract infection.[89]

Surgery

See main article: Surgery for benign prostatic hyperplasia.

If medical treatment is not effective, surgery may be performed. Surgical techniques used include the following:

Other less invasive surgical approaches (requiring spinal anesthesia) include:

Minimally invasive procedures

Some less invasive procedures are available according to patients' preferences and co-morbidities. These are performed as outpatient procedures with local anesthesia.

Alternative medicine

While herbal remedies are commonly used, a 2016 review found the herbs studied to be no better than placebos.[96] Particularly, several reviews found that saw palmetto extract, while one of the most commonly used, is no better than a placebo both in symptom relief and in decreasing prostate size.[97] [98] [99]

Epidemiology

Globally, benign prostatic hyperplasia affects about 94 million males .[7]

The prostate gets larger in most men as they get older. For a symptom-free man of 46 years, the risk of developing BPH over the next 30 years is 45%. Incidence rates increase from 3 cases per 1000 man-years at age 45–49 years, to 38 cases per 1000 man-years by the age of 75–79 years. While the prevalence rate is 2.7% for men aged 45–49, it increases to 24% by the age of 80 years.[100]

External links

Notes and References

  1. Kim EH, Larson JA, Andriole GL . Management of Benign Prostatic Hyperplasia . Annual Review of Medicine . 67 . 137–51 . 2016 . 26331999 . 10.1146/annurev-med-063014-123902 . Review . free .
  2. Silva V, Grande AJ, Peccin MS . Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction . The Cochrane Database of Systematic Reviews . 2019 . CD012044 . April 2019 . 4 . 30953341 . 6450803 . 10.1002/14651858.CD012044.pub2 .
  3. Web site: Prostate Enlargement (Benign Prostatic Hyperplasia) . NIDDK . 19 October 2017 . September 2014 . live . https://web.archive.org/web/20171004190055/https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia . 4 October 2017.
  4. Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J . Beta-sitosterols for benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 2 . CD001043 . 1999 . 2011 . 10796740 . 10.1002/14651858.CD001043 . Wilt TJ . 8407049 .
  5. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G . Pygeum africanum for benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 1 . CD001044 . 1998 . 1998 . 11869585 . 7032619 . 10.1002/14651858.CD001044 . Wilt TJ .
  6. Wilt TJ, Ishani A, Rutks I, MacDonald R . Phytotherapy for benign prostatic hyperplasia . Public Health Nutrition . 3 . 4A . 459–72 . December 2000 . 11276294 . 10.1017/S1368980000000549 . free .
  7. Awedew . Atalel Fentahun . Han . Hannah . Abbasi . Behzad . Abbasi-Kangevari . Mohsen . Ahmed . Muktar Beshir . Almidani . Omar . Amini . Erfan . Arabloo . Jalal . Argaw . Ayele Mamo . Athari . Seyyed Shamsadin . Atlaw . Daniel . Banach . Maciej . Barrow . Amadou . Bhagavathula . Akshaya Srikanth . Bhojaraja . Vijayalakshmi S . 2022-11-01 . The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 . The Lancet Healthy Longevity . en . 3 . 11 . e754–e776 . 10.1016/S2666-7568(22)00213-6 . 9640930 . 36273485.
  8. Chang RT, Kirby R, Challacombe BJ . Is there a link between BPH and prostate cancer? . The Practitioner . 256 . 1750 . 13–6, 2 . April 2012 . 22792684 .
  9. Web site: Urge incontinence . MedlinePlus . US National Library of Medicine . 26 October 2015 . live . https://web.archive.org/web/20151006031743/https://www.nlm.nih.gov/medlineplus/ency/article/001270.htm . 6 October 2015.
  10. Book: Incontinence and Stream Abnormalities . https://www.ncbi.nlm.nih.gov/books/NBK295/ . Clinical Methods: The History, Physical, and Laboratory Examinations . 3rd . Boston . Butterworths . 1990 . 21250138 . White JR, O'Brien III DP, Walker HK, Hall WD, Hurst JW . 9780409900774 .
  11. Robinson J . Post-micturition dribble in men: causes and treatment . Nursing Standard . 22 . 30 . 43–6 . 11 February 2008 . 18459613 . 10.7748/ns2008.04.22.30.43.c6440 .
  12. Sarma AV, Wei JT . Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms . The New England Journal of Medicine . 367 . 3 . 248–57 . July 2012 . 22808960 . 10.1056/nejmcp1106637 .
  13. Web site: Urination – difficulty with flow . MedlinePlus . US National Library of Medicine . 26 October 2015 . live . https://web.archive.org/web/20151006115737/https://www.nlm.nih.gov/medlineplus/ency/article/003143.htm . 6 October 2015.
  14. Web site: Urination – painful . MedlinePlus . US National Library of Medicine . 26 October 2015 . live . https://web.archive.org/web/20151006110537/https://www.nlm.nih.gov/medlineplus/ency/article/003145.htm . 6 October 2015.
  15. Web site: Bladder outlet obstruction . MedlinePlus . US National Library of Medicine . 26 October 2015 . live . https://web.archive.org/web/20151006110511/https://www.nlm.nih.gov/medlineplus/ency/article/002238.htm . 6 October 2015.
  16. Web site: Benign Prostatic Hyperplasia. The Lecturio Medical Concept Library . 5 July 2021.
  17. Truzzi JC, Almeida FM, Nunes EC, Sadi MV . Residual urinary volume and urinary tract infection--when are they linked? . The Journal of Urology . 180 . 1 . 182–5 . July 2008 . 18499191 . 10.1016/j.juro.2008.03.044 .
  18. Wu CP, Gu FL . The prostate in eunuchs . Progress in Clinical and Biological Research . 370 . 249–55 . 1991 . 1924456 .
  19. Web site: Testosterone and Aging: Clinical Research Directions. . NCBI Bookshelf . 2 February 2015 . live . https://web.archive.org/web/20171105194336/https://www.ncbi.nlm.nih.gov/books/NBK216175/ . 5 November 2017.
  20. Web site: Proscar (finisteride) Prescribing Information . FDA – Drug Documents . Merck and Company . 2 March 2015 . live . https://web.archive.org/web/20160303231752/http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020180s037lbl.pdf . 3 March 2016.
  21. Bartsch G, Rittmaster RS, Klocker H . Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia . World Journal of Urology . 19 . 6 . 413–25 . April 2002 . 12022710 . 10.1007/s00345-002-0248-5 . 3257666 .
  22. Feldman BJ, Feldman D . The development of androgen-independent prostate cancer . Nature Reviews. Cancer . 1 . 1 . 34–45 . October 2001 . 11900250 . 10.1038/35094009 . 205020623 .
  23. Lagiou P, Mantzoros CS, Tzonou A, Signorello LB, Lipworth L, Trichopoulos D . Serum steroids in relation to benign prostatic hyperplasia . Oncology . 54 . 6 . 497–501 . 1997 . 9394847 . 10.1159/000227609 .
  24. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ . Serum sex hormones and measures of benign prostatic hyperplasia . The Prostate . 61 . 2 . 124–31 . October 2004 . 15305335 . 10.1002/pros.20080 . 24288565 .
  25. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ . 6 . Persistent intraprostatic androgen concentrations after medical castration in healthy men . The Journal of Clinical Endocrinology and Metabolism . 91 . 10 . 3850–6 . October 2006 . 16882745 . 10.1210/jc.2006-0968 . free .
  26. Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington CA, Nickel JC. 2008. Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 71. 2. 261–6. 10.1016/j.urology.2007.09.025. 2390769. 18308097.
  27. du Toit T, Swart AC. 2020. The 11β-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone. The Journal of Steroid Biochemistry and Molecular Biology. 196. 105497. 10.1016/j.jsbmb.2019.105497. 31626910. 204734045.
  28. 2022. Letter to the editor regarding the article "Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome". Urology. English. 10.1016/j.urology.2022.07.051. 0090-4295. 35987379. 251657694 . 169 . 273 . Masiutin MG, Yadav MK . subscription.
  29. 2022. Author reply. Urology. English. 10.1016/j.urology.2022.07.049. 35985522. 251658492. 0090-4295 . 169 . 273–274 . Dimitrakoff J, Nickel JC . subscription.
  30. Ho CK, Nanda J, Chapman KE, Habib FK . Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen . The Journal of Endocrinology . 197 . 3 . 483–91 . June 2008 . 18492814 . 10.1677/JOE-07-0470 . free .
  31. Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G . Androgen and prostatic stroma . Asian Journal of Andrology . 5 . 1 . 19–26 . March 2003 . 12646998 .
  32. Ansari MA, Begum D, Islam F . Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia . Annals of Saudi Medicine . 28 . 3 . 174–8 . 2008 . 18500180 . 6074428 . 10.4103/0256-4947.51727 . free .
  33. Gat Y, Gornish M, Heiblum M, Joshua S . Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment . Andrologia . 40 . 5 . 273–81 . October 2008 . 18811916 . 10.1111/j.1439-0272.2008.00883.x . 205442245 . free .
  34. Heber D . Prostate enlargement: the canary in the coal mine? . The American Journal of Clinical Nutrition . 75 . 4 . 605–6 . April 2002 . 11916745 . 10.1093/ajcn/75.4.605 . free .
  35. Zhang SX, Yu B, Guo SL, Wang YW, Yin CK . [Comparison of incidence of BPH and related factors between urban and rural inhabitants in district of Wannan] . Zhonghua Nan Ke Xue = National Journal of Andrology . 9 . 1 . 45–7 . February 2003 . 12680332 .
  36. Gu F . Changes in the prevalence of benign prostatic hyperplasia in China . Chinese Medical Journal . 110 . 3 . 163–6 . March 1997 . 9594331 .
  37. Chyou PH, Nomura AM, Stemmermann GN, Hankin JH . A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy . The Prostate . 22 . 3 . 253–64 . 1993 . 7683816 . 10.1002/pros.2990220308 . 32639108 .
  38. Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E . Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia . The American Journal of Clinical Nutrition . 75 . 4 . 689–97 . April 2002 . 11916755 . 10.1093/ajcn/75.4.689 . free .
  39. Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Tubaro A, Oelke M, Carini M, Maggi M . 6 . Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis . BJU International . 115 . 1 . 24–31 . January 2015 . 24602293 . 10.1111/bju.12728 . 22937831 . free . 2158/953282 . free .
  40. Wang J, Michelitsch T, Wunderlin A, Mahadeva R . Aging as a consequence of misrepair--A novel theory of aging. . Nature Precedings . March 2009 . 10.1038/npre.2009.2988.1 . free . 0904.0575 .
  41. Tissue fibrosis: a principal evidence for the central role of Misrepairs in aging . Wang-Michelitsch J, Michelitsch T . 2015 . cs.DM . 1503.01376 .
  42. Roehrborn . Claus G . Benign Prostatic Hyperplasia: An Overview . Rev Urol . 2005 . 7 . Suppl 9 . S3–S14 . 16985902 . 1477638 .
  43. Wasserman NF . Benign prostatic hyperplasia: a review and ultrasound classification . Radiologic Clinics of North America . 44 . 5 . 689–710, viii . September 2006 . 17030221 . 10.1016/j.rcl.2006.07.005 .
  44. Ojewola RW, Tijani KH, Fatuga AL, Onyeze CI, Okeke CJ . Management of a giant prostatic enlargement: Case report and review of the literature . The Nigerian Postgraduate Medical Journal . 27 . 3 . 242–247 . 2020 . 32687126 . 10.4103/npmj.npmj_69_20 . Medknow . 220652018 . free .
  45. Parsons JK . Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors . Current Bladder Dysfunction Reports . 5 . 4 . 212–218 . December 2010 . 21475707 . 3061630 . 10.1007/s11884-010-0067-2 .
  46. Eid K, Krughoff K, Stoimenova D, Smith D, Phillips J, O'Donnell C, Barqawi A . Validation of the Urgency, Weak stream, Incomplete emptying, and Nocturia (UWIN) score compared with the American Urological Association Symptoms Score in assessing lower urinary tract symptoms in the clinical setting . Urology . 83 . 1 . 181–5 . January 2014 . 24139351 . 10.1016/j.urology.2013.08.039 .
  47. Gammie A, Drake MJ . The fundamentals of uroflowmetry practice, based on International Continence Society good urodynamic practices recommendations . Neurourology and Urodynamics . 37 . S6 . S44–S49 . August 2018 . 30614059 . 10.1002/nau.23777 . 58586667 . free .
  48. Foo KT . June 2013 . The Role of Transabdominal Ultrasound in Office Urology . Proceedings of Singapore Healthcare . en . 22 . 2 . 125–130 . 10.1177/201010581302200208 . 74205747 . 2010-1058. free .
  49. Aprikian S, Luz M, Brimo F, Scarlata E, Hamel L, Cury FL, Tanguay S, Aprikian AG, Kassouf W, Chevalier S . 6 . Improving ultrasound-based prostate volume estimation . BMC Urology . 19 . 1 . 68 . July 2019 . 31340802 . 6657110 . 10.1186/s12894-019-0492-2 . free .
  50. Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A . Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation . Radiographics . 36 . 1 . 162–175 . January 2016 . 26587887 . 5496681 . 10.1148/rg.2016150030 .
  51. Singh S, Martin E, Tregidgo HF, Treeby B, Bandula S . Prostatic calcifications: Quantifying occurrence, radiodensity, and spatial distribution in prostate cancer patients . Urologic Oncology . 39 . 10 . 728.e1–728.e6 . October 2021 . 33485763 . 8492071 . 10.1016/j.urolonc.2020.12.028 .
  52. Mitterberger M, Horninger W, Aigner F, Pinggera GM, Steppan I, Rehder P, Frauscher F . Ultrasound of the prostate . Cancer Imaging . 10 . 1. 40–48 . March 2010 . 20199941 . 2842183 . 10.1102/1470-7330.2010.0004 .
  53. Lee JS, Chung BH . Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens . Urologia Internationalis . 78 . 4 . 323–327 . 2007 . 17495490 . 10.1159/000100836 . 10731245 .
  54. Hwang EC, Gandhi S, Jung JH, Imamura M, Kim MH, Pang R, Dahm P . Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 2018 . CD007360 . October 2018 . 10 . 30306544 . 6516835 . 10.1002/14651858.CD007360.pub3 .
  55. Silva V, Grande AJ, Peccin MS . Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction . The Cochrane Database of Systematic Reviews . 2019 . 4 . CD012044 . April 2019 . 30953341 . 6450803 . 10.1002/14651858.CD012044.pub2 .
  56. Web site: Benign prostatic hyperplasia . University of Maryland Medical Center . https://web.archive.org/web/20170425092640/http://umm.edu/health/medical/reports/articles/benign-prostatic-hyperplasia . 25 April 2017 .
  57. Silva V, Grande AJ, Peccin MS . Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction . The Cochrane Database of Systematic Reviews . 2019 . CD012044 . April 2019 . 4 . 30953341 . 6450803 . 10.1002/14651858.CD012044.pub2 . Cochrane Urology Group .
  58. Web site: Influence of voiding posture on urodynamic parameters in men: a literature review . De Jong Y, Pinckaers JH, Ten Brinck RM, Lycklama à Nijeholt AA . Nederlands Tijdschrift voor urologie . 2 July 2014 . live . https://web.archive.org/web/20140714200739/http://www.mednet.nl/wosmedia/1718/mictiehouding_tvu.pdf . 14 July 2014.
  59. de Jong Y, Pinckaers JH, ten Brinck RM, Lycklama à Nijeholt AA, Dekkers OM . Urinating standing versus sitting: position is of influence in men with prostate enlargement. A systematic review and meta-analysis . PLOS ONE . 9 . 7 . e101320 . 2014 . 25051345 . 4106761 . 10.1371/journal.pone.0101320 . 2014PLoSO...9j1320D . free .
  60. Silva J, Silva CM, Cruz F . Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? . Current Opinion in Urology . 24 . 1 . 21–8 . January 2014 . 24231531 . 10.1097/mou.0000000000000007 . 40954757 .
  61. Roehrborn CG, Nuckolls JG, Wei JT, Steers W . The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics . BJU International . 100 . 4 . 813–9 . October 2007 . 17822462 . 10.1111/j.1464-410X.2007.07061.x . free . 21001077 . BPH Registry and Patient Survey Steering Committee . 2027.42/73286 .
  62. Black L, Naslund MJ, Gilbert TD, Davis EA, Ollendorf DA . An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia . The American Journal of Managed Care . 12 . 4 Suppl . S99–S110 . March 2006 . 16551208 .
  63. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV . The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries . European Urology . 51 . 1 . 207–15; discussion 215–6 . January 2007 . 16846678 . 10.1016/j.eururo.2006.06.012 .
  64. MacDonald R, Wilt TJ . Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects . Urology . 66 . 4 . 780–8 . October 2005 . 16230138 . 10.1016/j.urology.2005.05.001 .
  65. Roehrborn CG . Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial . Urology . 58 . 6 . 953–9 . December 2001 . 11744466 . 10.1016/S0090-4295(01)01448-0 .
  66. MacDonald R, Wilt TJ, Howe RW . Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects . BJU International . 94 . 9 . 1263–70 . December 2004 . 15610102 . 10.1111/j.1464-410X.2004.05154.x . 6640867 . free .
  67. Djavan B, Marberger M . A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction . European Urology . 36 . 1 . 1–13 . 1999 . 10364649 . 10.1159/000019919 . 73366414 .
  68. Wilt TJ, Mac Donald R, Rutks I . Tamsulosin for benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 1 . CD002081 . 2003 . 12535426 . 10.1002/14651858.CD002081 . Wilt T .
  69. Santillo VM, Lowe FC . Treatment of benign prostatic hyperplasia in patients with cardiovascular disease . Drugs & Aging . 23 . 10 . 795–805 . 2006 . 17067183 . 10.2165/00002512-200623100-00003 . 24428368 .
  70. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations . The Journal of Urology . 170 . 2 Pt 1 . 530–47 . August 2003 . 12853821 . 10.1097/01.ju.0000078083.38675.79 . AUA Practice Guidelines Committee .
  71. Blankstein U, Van Asseldonk B, Elterman DS . BPH update: medical versus interventional management . The Canadian Journal of Urology . 23 . Suppl 1 . 10–5 . February 2016 . 26924590 . live . https://web.archive.org/web/20160807134146/http://www.canjurol.com/html/free-articles/V23I1S1F-07_DrElterman.pdf . 7 August 2016 .
  72. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J . 6 . Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia . The Journal of Urology . 171 . 3 . 1194–8 . March 2004 . 14767299 . 10.1097/01.ju.0000112918.74410.94 . Proscar Long-Term Efficacy Safety Study Group .
  73. Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R . Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study . BJU International . 113 . 4 . 623–35 . April 2014 . 24127818 . 10.1111/bju.12500 . 38243275 .
  74. Greco KA, McVary KT . The role of combination medical therapy in benign prostatic hyperplasia . International Journal of Impotence Research . 20 . Suppl 3 . S33-43 . December 2008 . 19002123 . 10.1038/ijir.2008.51 . free .
  75. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM . 6 . Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater . The Journal of Urology . 175 . 1 . 217–20; discussion 220–1 . January 2006 . 16406915 . 10.1016/S0022-5347(05)00041-8 . Medical Therapy of Prostatic Symptoms (MTOPS) Research Group .
  76. Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB . Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride . European Urology . 44 . 4 . 461–6 . October 2003 . 14499682 . 10.1016/s0302-2838(03)00367-1 .
  77. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS . 6 . The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group . The New England Journal of Medicine . 327 . 17 . 1185–91 . October 1992 . 1383816 . 10.1056/NEJM199210223271701 . free .
  78. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, Maggi M, Zattoni F, Carini M, Novara G . 6 . Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis . The Journal of Sexual Medicine . 11 . 6 . 1554–66 . June 2014 . 24708055 . 10.1111/jsm.12525 .
  79. Web site: Deters L . Benign Prostatic Hypertrophy Treatment & Management . Medscape . 14 November 2015 . live . https://web.archive.org/web/20151030062812/http://emedicine.medscape.com/article/437359-treatment . 30 October 2015.
  80. Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK . 6 . Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 2018 . CD010060 . November 2018 . 11 . 30480763 . 6517182 . 10.1002/14651858.CD010060.pub2 . Cochrane Urology Group .
  81. Wang Y, Bao Y, Liu J, Duan L, Cui Y . Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis . Lower Urinary Tract Symptoms . 10 . 1 . 84–92 . January 2018 . 29341503 . 10.1111/luts.12144 . 23929021 .
  82. Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK . 6 . Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 2018 . CD010060 . November 2018 . 11 . 30480763 . 6517182 . 10.1002/14651858.CD010060.pub2 .
  83. Web site: Hyperplasia (benign prostatic) – tadalafil (terminated appraisal) (TA273) . National Institute for Health and Clinical Excellence (NICE) . 23 January 2013 . 27 January 2013 . live . https://web.archive.org/web/20130224050938/http://guidance.nice.org.uk/TA273 . 24 February 2013.
  84. Web site: FDA approves Cialis to treat benign prostatic hyperplasia . U.S. Food and Drug Administration (FDA) . 7 May 2013 . live . https://web.archive.org/web/20130511011121/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm274642.htm . 11 May 2013.
  85. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial . JAMA . 296 . 19 . 2319–28 . November 2006 . 17105794 . 10.1001/jama.296.19.2319 . free .
  86. Abrams P, Andersson KE . Muscarinic receptor antagonists for overactive bladder . BJU International . 100 . 5 . 987–1006 . November 2007 . 17922784 . 10.1111/j.1464-410x.2007.07205.x . 30983780 . free .
  87. Web site: Prostate enlargement (benign prostatic hyperplasia). Harvard Health Content. Harvard Health Publications. dead. https://web.archive.org/web/20150403012629/http://www.harvardhealthcontent.com/SpecialHealthReports/70%2CPA0212?Page=Section9. 3 April 2015. 2 February 2015.
  88. Wyndaele JJ . Complications of intermittent catheterization: their prevention and treatment . Spinal Cord . 40 . 10 . 536–541 . October 2002 . 12235537 . 10.1038/sj.sc.3101348 . free .
  89. Prieto JA, Murphy CL, Stewart F, Fader M . Intermittent catheter techniques, strategies and designs for managing long-term bladder conditions . The Cochrane Database of Systematic Reviews . 10 . 10 . CD006008 . October 2021 . 34699062 . 8547544 . 10.1002/14651858.CD006008.pub5 .
  90. Franco JV, Garegnani L, Escobar Liquitay CM, Borofsky M, Dahm P . Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia . The Cochrane Database of Systematic Reviews . 2021 . 6 . CD004135 . June 2021 . 34180047 . 8236484 . 10.1002/14651858.CD004135.pub4 .
  91. Web site: Transurethral resection of the prostate (TURP) - Risks. 2017-10-24. nhs.uk. en. 2020-03-08.
  92. Kuang M, Vu A, Athreya S . A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia . CardioVascular and Interventional Radiology . 40 . 5 . 655–663 . May 2017 . 28032133 . 10.1007/s00270-016-1539-3 . 12154537 .
  93. Pisco J, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, Duarte M, Oliveira AG . 6 . Prostate Embolization as an Alternative to Open Surgery in Patients with Large Prostate and Moderate to Severe Lower Urinary Tract Symptoms . Journal of Vascular and Interventional Radiology . 27 . 5 . 700–8 . May 2016 . 27019980 . 10.1016/j.jvir.2016.01.138 .
  94. McNicholas TA . Benign prostatic hyperplasia and new treatment options - a critical appraisal of the UroLift system . Medical Devices: Evidence and Research. 9 . 115–23 . May 2016 . 27274321 . 4876946 . 10.2147/MDER.S60780 . free .
  95. Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D . Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up . BJU International . 116 . 2 . 278–87 . August 2015 . 25382816 . 10.1111/bju.12982 . 2318/1623503 . 5712711 . free .
  96. Keehn A, Taylor J, Lowe FC . Phytotherapy for Benign Prostatic Hyperplasia . Current Urology Reports . 17 . 7 . 53 . July 2016 . 27180172 . 10.1007/s11934-016-0609-z . 25609876 .
  97. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL . Saw palmetto for benign prostatic hyperplasia . The New England Journal of Medicine . 354 . 6 . 557–566 . February 2006 . 16467543 . 10.1056/NEJMoa053085 . 13815057 . free .
  98. Dedhia RC, McVary KT . Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia . The Journal of Urology . 179 . 6 . 2119–2125 . June 2008 . 18423748 . 10.1016/j.juro.2008.01.094 .
  99. Franco JV, Trivisonno L, Sgarbossa NJ, Alvez GA, Fieiras C, Escobar Liquitay CM, Jung JH . Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement . The Cochrane Database of Systematic Reviews . 2023 . 6 . CD001423 . June 2023 . 37345871 . 10286776 . 10.1002/14651858.CD001423.pub4 .
  100. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R . 6 . Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project . European Urology . 42 . 4 . 323–8 . October 2002 . 12361895 . 10.1016/S0302-2838(02)00354-8 . Triumph Pan European Expert Panel .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Benign prostatic hyperplasia".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.